Calibrate Reviews Liraglutide
Available but rarely the starting point. In practice it appears where the weekly agents are contraindicated or unavailable rather than as a deliberate cost step.
Sold as Saxenda, Victoza · Reviewed September 19, 2026
What “Adjunct” means here
Available and used, but not the centre of the protocol — typically alongside or after another agent.
The pairing
How Calibrate handles Liraglutide
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- Adjunct
- Gating
- Clinician judgment. Not positioned as a required rung before the weekly agents.
- Prescribes directly
- Yes
- Step therapy
- No
- Prior authorization
- Yes
- Titration protocol
- Physician-directed titration with mandatory quarterly video visits and lab monitoring
- Off-ramp
- One-year maintenance curriculum after target weight, coach-led
- Care team
- Board-certified physicians, Nurse practitioners, Accountability coaches
Ask Calibrate this
What share of your book actually starts on liraglutide, and is it ever used as a cost-motivated first trial?
Watch out
The weight-loss guarantee excludes pharmacy spend entirely. It protects the program fee, not your budget.
The molecule
Liraglutide in one page
The first-generation daily GLP-1. Lower efficacy than the weekly agents, but generic entry has made it the cheapest genuine GLP-1 option and a credible step-therapy rung.
Clinical profile
- Drug class
- GLP-1 receptor agonist
- Brand names
- Saxenda — Chronic weight managementVictoza — Type 2 diabetes
- Mechanism
- Single GLP-1 receptor agonist with a shorter half-life than the weekly agents, requiring daily administration to maintain effect.
- Administration
- Once-daily subcutaneous injection. Daily dosing is the main adherence disadvantage versus weekly agents.
- Titration
- Weekly dose escalation over roughly a month to the maintenance dose — a substantially shorter ladder than the weekly agents.
- Typical result
- Average body-weight reduction in the high single digits as a percentage — roughly half what the newer agents produce, though achieved faster and at a fraction of the cost.
- Generic available
- Yes
Known side effects
- Gastrointestinal effects similar in kind to the weekly agents
- Injection-site reactions somewhat more common given daily administration
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
What benefits teams need to know
This is your step-therapy rung
Generic availability makes liraglutide the only GLP-1 that can sit meaningfully below the weekly agents on cost. A vendor that will genuinely trial it before escalating has a real cost-control mechanism; one that lists it and never uses it does not.
Adherence is the honest tradeoff
Daily injection produces worse persistence than weekly dosing. A step-therapy protocol built on this molecule needs to distinguish members who failed on efficacy from members who failed on adherence, because they warrant different escalation decisions.
Alternatives
Other vendors and Liraglutide
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Omada Health Coaching companion | Companion support | 8.4 | $32–$58 |
| Form Health Full-service clinical | First-line | 8.0 | $58–$105 |
| Teladoc Health Navigation & orchestration | Adjunct | 7.4 | $18–$44 |
| 9amHealth Metabolic specialist | Adjunct | 7.3 | $34–$72 |
| Transcarent Navigation & orchestration | Orchestrated | 7.1 | $12–$32 |
| WeightWatchers Clinic Consumer-brand clinical | Adjunct | 6.9 | $30–$68 |
Same vendor
Calibrate across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
A first-line option with no required lower-cost trial. Physician-directed titration with quarterly video visits and lab monitoring is genuinely above the market norm for clinical intensity.
Treated interchangeably with semaglutide as a first-line choice, selected on tolerability and coverage rather than on a cost hierarchy. The quarterly physician cadence carries across.
Used alongside incretin therapy for members with glycemic indications rather than as a standalone weight intervention or a required first rung.